Companies › Exciva
2 active drug programs in 6 registered trials: 3 Phase 2, 3 Phase 1; Neurology, Oncology, Other, Psychiatry; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dextromethorphan (EXV-802) Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia; Obsessive-Compulsive Disorder; Hodgkin Lymphoma; Psychedelic Effects in Healthy Volunteers … | Jan 2029 |
| EXV-801 Sigma-1 receptor agonist | SIGMAR1 | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06383338 | Dextromethorphan (EXV-802) | Phase 1 | Hodgkin Lymphoma | Oncology | Nov 2026 |
| NCT04899687 | Dextromethorphan (EXV-802) | Phase 2 | Obsessive-Compulsive Disorder | Psychiatry | Apr 2027 |
| NCT06772753 | Dextromethorphan (EXV-802) | Phase 1 | Psychedelic Effects in Healthy Volunteers | Other | Jun 2027 |
| NCT07284472 | Dextromethorphan (EXV-802) | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia | Neurology | Jan 2029 |
| NCT07284472 | EXV-801 | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia | Neurology | Jan 2029 |
| NCT07593222 | Dextromethorphan (EXV-802) | Phase 1 | Major Depression | Psychiatry | Dec 2030 |
CSPC Ouyi Pharmaceutical UCB BIOSCIENCES Anavex Life Sciences Pentixapharm Zogenix Syndeio Biosciences SHINKEI Therapeutics Aptinyx Johnson & Johnson (Janssen)
Aptinyx SHINKEI Therapeutics Syndeio Biosciences Spinogenix Shanghai Auzone Biological Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.